Effect of clopidogrel added to aspirin in patients with atrial fibrillation

October 2009
Australian Journal of Pharmacy;Oct2009, Vol. 90 Issue 1073, p68
The article discusses the effects of clopidogrel when added to aspirin which are given to patients with atrial fibrillation. It notes that a study was made to investigate the hypothesis that adding clopidogrel to aspirin will reduce the risk of vascular events in patients with atrial fibrillation. The study revelas that in patients with atrial fibrillation wherein vitamin K-antagonist therapy was unsuitable, the addition of clopidogrel to aspirin reduces the risk of major vascular events.


Related Articles

  • New anticoagulant option 'could replace warfarin'. Tanday, Sanjay // GP: General Practitioner;9/4/2009, p7 

    The article presents a research by Dr. Sarah Jarvis and colleagues, which states that dabigatran, an alternative for Clopidogrel, has been found that reduced bleeding. Researchers gave 18,113 atrial fibrillation (AF) patients either dabigatran 110mg or 150mg twice daily, or an adjusted dose of...

  • Drug Therapy for AF: Current Options and Future Promise. Jacobson, Anne // MD Conference Express;Dec2009, p32 

    The article focuses on the restoration and maintenance of sinus rhythm in atrial fibrillation (AF) patients with high risk of stroke or death. It discusses the rhythm control and rate control strategies which are intended for the pharmacological management of stroke risk in AF. A trial shows...

  • Clopidogrel + aspirin in atrial fibrillation.  // Internal Medicine Alert;7/15/2009, Vol. 31 Issue 13, p103 

    The article presents a study that adds clopidogrel (CPG) to aspirin (ASA) for additional antithrombotic efficacy for atrial fibrillation (FIB) patients. FIB patients with indications for coumadin were distributed to ASA alone or ASA with CPG. At a follow-up of 3.6 years, there was a significant...

  • A Clinical Profile of Idiopathic Atrial Fibrillation. Peter, Robert H.; Gracey, Jack G.; Beach, Thomas B. // Annals of Internal Medicine;Jun68, Vol. 68 Issue 6, p1288 

    Presents information on a study which observed patients with idiopathic atrial fibrillation. Methodology; Results; Discussion.

  • Neue orale Antikoagulanzien beim Vorhofflimmern. Veitkamp, R.; Hacke, W. // Der Nervenarzt;Feb2011, Vol. 82 Issue 2, p180 

    ial fibrillation (AF) causes at least 20% of all ischemic strokes. In large randomized trials of primary and secondary stroke prevention, anticoagulation with vitamin K antagonists (VKA) protected much more efficiently than antiplatelet agents against stroke. Because of the problematic...

  • Meta-analysis of clinical outcomes of maze-related surgical procedures for medically refractory atrial fibrillation. Reston, James T.; Shuhaiber, Jeffrey H. // European Journal of Cardio-Thoracic Surgery;Nov2005, Vol. 28 Issue 5, p724 

    Abstract: Objective: Although maze-related surgical procedures have shown success at eliminating atrial fibrillation, published controlled studies have generally been too small to detect clinically significant differences in morbidity and mortality. We pooled available studies to determine...

  • HOSPITALIZATONS FOR IRREGULAR HEART BEAT ON THE INCREASE.  // Mind, Mood & Memory;Aug2014, Vol. 10 Issue 8, p1 

    The article focuses on the increased number of hospitalizations for patients with a heart rhythm disorder or atrial fibrillation which is attributed to an increase in the prevalence of risk factors such as high blood pressure, lung disease, and sleep apnea in the population.

  • Warfarin.  // Reactions Weekly;12/1/2007, Issue 1180, p38 

    The article describes the case of an 84-year-old man who developed a possible case of "purple toe" syndrome following warfarin therapy for atrial fibrillation. The patient's toes were painful and had turned purple. Prior to a dental procedure, warfarin was withheld and his symptoms were...

  • The P450 system and CV outcomes with clopidogrel. Kuritzky, Louis // Internal Medicine Alert;12/15/2010 Supplement, p183 

    The article offers information on the impact of the P450 system and clopidogrel on the reduction of cardio-vascular events (CV) among people with atrial fibrillation.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics